CN116508991A - 解酒组合物及其制备方法和应用 - Google Patents
解酒组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN116508991A CN116508991A CN202310560356.XA CN202310560356A CN116508991A CN 116508991 A CN116508991 A CN 116508991A CN 202310560356 A CN202310560356 A CN 202310560356A CN 116508991 A CN116508991 A CN 116508991A
- Authority
- CN
- China
- Prior art keywords
- oil
- pine nut
- composition according
- phase
- hangover
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 230000002075 anti-alcohol Effects 0.000 title claims abstract description 36
- 238000002360 preparation method Methods 0.000 title abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 38
- 239000010490 pine nut oil Substances 0.000 claims abstract description 34
- 235000019496 Pine nut oil Nutrition 0.000 claims abstract description 32
- 206010019133 Hangover Diseases 0.000 claims abstract description 26
- 240000008042 Zea mays Species 0.000 claims abstract description 21
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 21
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 21
- 235000005822 corn Nutrition 0.000 claims abstract description 21
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 20
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 20
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 11
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 11
- 239000008157 edible vegetable oil Substances 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract 2
- 239000012071 phase Substances 0.000 claims description 50
- 238000010008 shearing Methods 0.000 claims description 46
- 239000003921 oil Substances 0.000 claims description 29
- 235000019198 oils Nutrition 0.000 claims description 29
- -1 glycerol fatty acid ester Chemical class 0.000 claims description 24
- 238000002156 mixing Methods 0.000 claims description 23
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 21
- 239000000194 fatty acid Substances 0.000 claims description 21
- 229930195729 fatty acid Natural products 0.000 claims description 21
- 238000010438 heat treatment Methods 0.000 claims description 20
- 238000005303 weighing Methods 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- 229930006000 Sucrose Natural products 0.000 claims description 12
- 239000005720 sucrose Substances 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 10
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 9
- 235000019864 coconut oil Nutrition 0.000 claims description 7
- 239000003240 coconut oil Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 102000011632 Caseins Human genes 0.000 claims description 5
- 108010076119 Caseins Proteins 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 229940080237 sodium caseinate Drugs 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 244000272459 Silybum marianum Species 0.000 claims description 4
- 235000010841 Silybum marianum Nutrition 0.000 claims description 4
- 235000003599 food sweetener Nutrition 0.000 claims description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 239000003765 sweetening agent Substances 0.000 claims description 4
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims description 3
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 claims description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 2
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 235000021323 fish oil Nutrition 0.000 claims description 2
- 239000010460 hemp oil Substances 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000008347 soybean phospholipid Substances 0.000 claims description 2
- CODAYFPFZXWNLD-UHFFFAOYSA-N 2-hydroxypropanoyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)C(C)O CODAYFPFZXWNLD-UHFFFAOYSA-N 0.000 claims 1
- 240000007263 Pinus koraiensis Species 0.000 claims 1
- 235000011615 Pinus koraiensis Nutrition 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 235000010746 mayonnaise Nutrition 0.000 claims 1
- 239000008268 mayonnaise Substances 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 235000001459 whitebark Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 230000035622 drinking Effects 0.000 abstract description 18
- 239000000839 emulsion Substances 0.000 abstract description 16
- 239000002994 raw material Substances 0.000 abstract description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 121
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 44
- 238000003756 stirring Methods 0.000 description 34
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- 102000019197 Superoxide Dismutase Human genes 0.000 description 23
- 108010012715 Superoxide dismutase Proteins 0.000 description 23
- 238000000265 homogenisation Methods 0.000 description 17
- 210000004185 liver Anatomy 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 16
- 230000006378 damage Effects 0.000 description 11
- 230000004060 metabolic process Effects 0.000 description 11
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- 230000001954 sterilising effect Effects 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 9
- 210000003022 colostrum Anatomy 0.000 description 8
- 235000021277 colostrum Nutrition 0.000 description 8
- 238000011049 filling Methods 0.000 description 8
- 238000004321 preservation Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 208000007848 Alcoholism Diseases 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 201000007930 alcohol dependence Diseases 0.000 description 4
- 210000001156 gastric mucosa Anatomy 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229940083466 soybean lecithin Drugs 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 229960002986 dinoprostone Drugs 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 3
- 230000002633 protecting effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 101150038502 ALDH2 gene Proteins 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 2
- 101150018665 MAPK3 gene Proteins 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 150000005693 branched-chain amino acids Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960002152 chlorhexidine acetate Drugs 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000004149 ethanol metabolism Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 235000020778 linoleic acid Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- HXQHFNIKBKZGRP-URPRIDOGSA-N (5Z,9Z,12Z)-octadecatrienoic acid Chemical compound CCCCC\C=C/C\C=C/CC\C=C/CCCC(O)=O HXQHFNIKBKZGRP-URPRIDOGSA-N 0.000 description 1
- KHICUSAUSRBPJT-UHFFFAOYSA-N 2-(2-octadecanoyloxypropanoyloxy)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(O)=O KHICUSAUSRBPJT-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 1
- 235000018783 Dacrycarpus dacrydioides Nutrition 0.000 description 1
- 240000006055 Dacrydium cupressinum Species 0.000 description 1
- 235000018782 Dacrydium cupressinum Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101710165567 Extracellular signal-regulated kinase 1 Proteins 0.000 description 1
- 101710165576 Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 102000009645 Mitochondrial Aldehyde Dehydrogenase Human genes 0.000 description 1
- 108010009513 Mitochondrial Aldehyde Dehydrogenase Proteins 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000013697 Pinus resinosa Nutrition 0.000 description 1
- 240000007320 Pinus strobus Species 0.000 description 1
- 235000008578 Pinus strobus Nutrition 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- HXQHFNIKBKZGRP-UHFFFAOYSA-N Ranuncelin-saeure-methylester Natural products CCCCCC=CCC=CCCC=CCCCC(O)=O HXQHFNIKBKZGRP-UHFFFAOYSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003574 free electron Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940071209 stearoyl lactylate Drugs 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提出了一种解酒组合物及其制备方法和应用,解酒组合物包括松子油、磷脂、食用油、SOD、玉米低聚肽、乳化剂和水,通过将上述原料制备成乳剂得到解酒组合物,该解酒组合物能够快速被人体吸收,其中松子油、SOD、玉米低聚肽和磷脂能够分别提升肝脏活性、保护胃肠道,降低胃肠道对酒精的吸收,并提供人体分解酒精必须的底物,从而达到快速解酒,抑制酒精吸收,保护胃肠道和肝脏的功效。本发明的解酒组合物可以用于食品或医疗领域。本发明的解酒组合物可以明显改善饮酒带来的身体不适,且无明显不良影响。
Description
技术领域
本发明涉及功能食品技术领域,尤其涉及一种解酒组合物及其制备方法和应用。
背景技术
酒精通过胃肠道吸收,经过肝脏中乙醇脱氢酶和乙醛脱氢酶的氧化最终形成乙酸,乙酸则可以直接被人体利用。然而,肝脏分解乙醇的能力有一定的限度,大量饮酒会导致血液中乙醇的含量急剧升高,导致急性酒精中毒。急性酒精中毒后,可能引起长时间的身体不适,例如头痛、头晕、失眠、乏力、胃部不适和恶心,甚至于精神迟钝。而长期过量饮酒不仅会损害肝、胃、脾等内脏器官,还可能导致酒精性肝炎和肝硬化等疾病,进一步有癌变的风险。
常规解酒产品主要是基于中药的配伍,强调肝脏活性的作用,通过提升肝脏活性从而达到解酒效果,该解酒的作用机制相对单一,解酒的效果难以达到预期,提供一种能够从多方面进行作用,具有更高的解酒效率的解酒组合物成为目前亟需解决的技术问题。
发明内容
有鉴于此,本发明提出了一种解酒组合物及其制备方法和应用,旨在提供一种能够快速解酒从而降低酒精对人体损害的组合物。
本发明的技术方案是这样实现的:本发明提供了一种解酒组合物,其包括:松子油、磷脂、食用油、SOD、玉米低聚肽、乳化剂和水。
以上实施方式中,松子油、磷脂和食用油组成油相,SOD和玉米低聚肽组成水相,在乳化剂的作用下,两相成分均匀分散形成乳液,乳液粒子的平均粒径在150nm-500nm,制成乳液形式的解酒组合物可以更快速地被肠道吸收,同时油相部分附着在胃肠道黏膜表面,具有一定的阻隔作用,降低了胃肠道对酒精的吸收,从源头上降低了酒精对人体造成的损害。
松子具有散水气,润五脏,解酒毒的功效,一方面,松子油中含有皮诺敛酸,皮诺敛酸具有养肝、护肝、治疗保护肠胃疾病和增强免疫力的作用;另一方面,松子油中富含多种维生素、糖原、氨基酸等成分,可以帮助净化肝脏、强化肝功能、解肝毒;而且松子油可以提高人体内抗氧化酶的活性,降低丙二醛的含量,具有抗氧化作用,对于肝脏中的活性物质如:超氧化物歧化酶、谷光甘肽等具有解酒的活性物质具有保护作用。松籽油中的含有的甾体及多酚化合物,能使自由基的游离电子配对,从而减少或免除自由基或酒精、乙醛等对人体造成的损伤,并加快生物体物质和能量的自我更新,也可以促进免疫细胞的活力,加强免疫系统抵抗损伤的作用。同时,松籽油对血清中超氧化物歧化酶(SOD)水平具有一定的增加作用,增加血清中总抗氧化能力(T-AOC)水平,对于血液中酒精有抵抗作用。
同时,酒精不仅会对肝脏造成损伤,还会对胃肠道造成刺激和损伤,松籽油中含亚油酸约44%-67%。亚油酸是合成前列腺素的前体,前列腺素(prostaglandins)存在于许多器官,有着多种多样的生理功能,奶中的前列腺素可以防止婴儿消化道损伤。摄食富含多不饱和脂肪酸的饮食,特别是LA、AA、LNA的植物油,可能是防治溃疡病的一个有效途径。研究认为前列腺素E2是细胞保护因子,在胃粘膜防御机制中起重要作用,前列腺素E2是胃粘膜上皮细胞不断合成和分泌的由不饱和脂肪酸组成的活性物质,对其自身有较强的保护作用。保护机制包括:(1)减少H+逆向弥散,保护胃粘膜屏障;(2)刺激胃粘膜表面活性磷脂的分泌,增加粘膜表面粘液厚度,增强对损伤刺激的修复功能;(3)刺激粘膜基底细胞向表面移行,促进胃粘膜上皮细胞再生;(4)增加粘膜血流量;(5)抑制肥大细胞脱颗粒,稳定溶酶体膜等;(6)刺激多种生长因子的产生而促进组织修复。
玉米肽中含有丰富的谷氨酸,摄入玉米肽,能够补充血液中因受酒精抑制而减少的氨基酸,从而维持脑细胞的能量供应和神经活动,减少酒精造成的神经系统症状。玉米低聚肽能够促进酒精的代谢,降低酒精的血浆浓度的功效,玉米低聚肽可以提高乙醇脱氢酶的活性,加速酒精的代谢。同时玉米低聚肽含有丰富的丙氨酸、支链氨基酸和脯氨酸,服用后可以显著降低血乙醇浓度,提高血中丙氨酸、支链氨基酸和脯氨酸的浓度并提供更多的NAD+,NAD+是乙醛脱氢酶的辅酶,可以提高乙醛脱氢酶的活性,促进乙醛代谢,从而降低血乙醛的浓度,达到降低醉酒程度和醒酒的作用。
SOD全称超氧化物歧化酶,简称“肝蛋白”,SOD是人体中唯一以自由基为底物的特异性清除剂,饮酒后乙醇会消耗大量的SOD,补充SOD也可以加速乙醇的代谢,减少乙醇对人体的损害。ALDH2基因正常的人能够及时将乙醛分解;而当ALDH2存在缺陷时,乙醛只能在肝脏中蓄积,被肝脏中的氧化酶P450慢慢氧化代谢,引起面部潮红、心跳加速、头晕目眩、恶心呕吐等不适、更容易对内脏器官造成伤害。约30%-50%的中国人属于ALDH2基因异常人群,这意味着喝酒对我们而言更加致命。根据酒精代谢的相关化学反应,乙醇与乙醛的代谢均涉及一种人体内关键辅酶,生物蛋白酶的参与。服用SOD能够快速提高肝脏中健康活性细胞以及生物蛋白酶的含量,加速酒精的分解代谢,从而发挥快速解酒的作用。
SOD还能够阻止乙醇对Erk1/2磷酸化的抑制作用。细胞外信号调节激酶1/2(Erk1/2)在肝脏细胞在代谢、细胞周期和细胞存活中发挥重要作用。SOD能够提高肝脏健康活性细胞水平,通过Atf3和Erk1/2信号传导阻止乙醇诱导的ALT和AST升高,并改变25%受乙醇代谢调节的基因的表达,对酒精性肝损伤的缓解具有重要意义。
磷脂不仅可以提供乳化作用,同时磷脂还具有解酒作用,其可以促进肝细胞活化和再生,增强肝功能,有助于提高对血液中乙醇和乙醛的代谢,降低酒精性的肝硬化、脂肪肝等疾病的患病率。
在一些实施方式中,解酒组合物按质量百分比为100%计算,包括:
在一些实施方式中,松子油包括:华山松子油、白皮松子油、长白松子油和红松子油中的至少一种。
在一些实施方式中,磷脂包括:大豆磷脂、改性大豆磷脂、蛋黄卵磷脂和磷脂酰胆碱中的至少一种。
在一些实施方式中,食用油包括:大豆油、中链甘油三酸酯、水飞蓟籽油、椰子油、美藤果油、火麻油和鱼油中的至少一种。
在一些实施方式中,乳化剂包括:甘油脂肪酸酯、蔗糖脂肪酸酯、酪蛋白酸钠、蔗糖酯、山梨醇酐脂肪酸酯、丙二醇脂肪酸酯、硬脂酰乳酸盐和双乙酰酒石酸单甘油酯中的至少一种。
在一些实施方式中,解酒组合物还包括助剂,助剂包括pH调节剂、稳定剂和甜味剂中的至少一种,助剂的质量百分比为0.1-1.5%。
在一些实施方式中,助剂包括:
pH调节剂0.1-0.5%,和/或
稳定剂0.1-0.5%,和/或
甜味剂0.1-0.5%。
在一些实施方式中,pH调节剂包括:碳酸钠、碳酸钾、L-赖氨酸、L-精氨酸、L-组氨酸和氢氧化钠中的至少一种。
在一些实施方式中,稳定剂包括:胶质、糊精和糖酯中的至少一种。
在一些实施方式中,甜味剂包括胶质、糊精和糖脂中的至少一种。
另一方面,本发明还提供一种解酒组合物的制备方法,其包括如下步骤:
按照配方称取SOD、玉米低聚肽和部分乳化剂,与水混合后加热至30-90℃,混合均匀得到水相;
按照配方称取松子油、磷脂、食用油和剩余的乳化剂,加热至40-80℃,混合均匀得到油相;
在一些实施方式中,混合油相和水相时,将油相缓慢加入至水相,加入的同时进行剪切搅拌,剪切搅拌完毕后用高压均质机进行均质处理,得到解酒组合物。
在一些实施方式中,将油相缓慢加入水相时进行剪切处理,剪切时间为5-30min。
在一些实施方式中,高压均质时,高压均质机的参数包括:一级压力为200-800bar,二级压力为30-100bar,高压均质3-10次,均质后可以加入助剂。
在一些实施方式中,还包括:在对解酒组合物进行包装后进行灭菌处理。
以上实施方式中,灭灭菌温度为100℃-121℃,灭菌时间为5-30min。
第三方面,本发明还提供一种上述解酒组合物在保健食品或药物中的应用。
本发明的解酒组合物及其制备方法和应用相对于现有技术具有以下有益效果:
本发明提供的解酒组合物采用乳剂形式,将难容的油性有效成分制成微小乳粒,更容易被肠道吸收,乳剂中的水性成分能够通过胞吞作用快速被肠道吸收,同时部分附着在胃肠道表面的油脂能够对胃肠道起保护作用,降低胃肠道中乙醇的吸收率,同时原料中所采用的松子油、玉米低聚肽、超氧化物歧化酶和磷脂的组合配方具有优秀的快速降低血液乙醇乙醛浓度、改善头晕头痛的效果,松子油不仅保护肠胃,同时解酒毒提高肝活性,玉米低聚肽促进乙醇和乙醛代谢,快速降低血液中乙醇含量,SOD促进肝脏对乙醇和乙醛进行快速代谢,同时SOD可以改变部分受乙醇代谢调节的基因的表达,达到一定预防和治疗酒精性脂肪肝的目的,相比常规的提高肝活性的解酒组合物而言,本发明的解酒组合物通过各组分的配合协同,起到了具有更快速更持久的解酒效果。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1为本发明实施例1中各周期的呼气酒精含量的折线图;
图2为本发明实施例1中各周期血液中乙醇浓度的折线图;
图3为本发明实施例1中各周期血液中乙醛浓度的折线图。
具体实施方式
下面将结合本发明实施方式,对本发明实施方式中的技术方案进行清楚、完整地描述,显然,所描述的实施方式仅仅是本发明一部分实施方式,而不是全部的实施方式。基于本发明中的实施方式,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施方式,都属于本发明保护的范围。
除非另外定义,否则本文使用的所有技术术语和科学属于具有与本发明实施例所属技术领域普通技术人员通常理解相同的含义。如果此部分中陈述的定义与通过引用纳入本文的所述专利、专利申请、公布的专利申请和其他出版物中陈述的定义相反或其他方面不一致,此部分中列出的定义优先与通过引用纳入本文中的定义。
实施例1
称取松子油20份、大豆磷脂20份、椰子油30份、蔗糖脂肪酸酯1份,混合后加入剪切搅拌机中,加热至60℃,保温剪切搅拌处理20min,得到油相;
称取SOD5份、玉米低聚肽5份、酪蛋白酸钠10份、水909份,混合加入剪切搅拌机中,加热至60℃,搅拌均匀,得到水相;
将油相缓慢加入至水相中,加入的过程中进行剪切搅拌,完全加入后剪切搅拌20min,得到初乳;
设置高压均质机的参数为:一级压力200bar,二级压力为30bar,对初乳进行高压均质处理3次,均质完成后灌装处理,每个单元灌装30ml;
灌装完成后,在121℃下,灭菌处理20min,得到解酒组合物。
实施例2
称取松子油2份、改性大豆磷脂30份、水飞蓟籽油300份、蔗糖脂肪酸酯12份,混合后加入剪切搅拌机中,加热至30℃,保温剪切搅拌处理20min,得到油相;
称取SOD0.1份、玉米低聚肽50份、蔗糖脂肪酸酯8份、水597.9份,混合加入剪切搅拌机中,加热至40℃,搅拌均匀,得到水相;
将油相缓慢加入至水相中,加入的过程中进行剪切搅拌,完全加入后剪切搅拌20min,得到初乳;
设置高压均质机的参数为:一级压力300bar,二级压力为40bar,对初乳进行高压均质处理4次,均质完成后灌装处理,每个单元灌装30ml;
灌装完成后,在105-121℃下,灭菌处理20min,得到解酒组合物。
实施例3
称取松子油50份、蛋黄卵磷脂2份、水飞蓟籽油1份、蔗糖脂肪酸酯5份,混合后加入剪切搅拌机中,加热至40℃,保温剪切搅拌处理20min,得到油相;
称取SOD5份、玉米低聚肽1份、蔗糖脂肪酸酯15份、水921份,混合加入剪切搅拌机中,加热至50℃,搅拌均匀,得到水相;
将油相缓慢加入至水相中,加入的过程中进行剪切搅拌,完全加入后剪切搅拌20min,得到初乳;
设置高压均质机的参数为:一级压力500bar,二级压力为50bar,对初乳进行高压均质处理5次,均质完成后灌装处理,每个单元灌装30ml;
灌装完成后,在105-121℃下,灭菌处理20min,得到解酒组合物。
实施例4
称取松子油50份、磷脂酰胆碱30份、椰子油200份、酪蛋白酸钠1份,混合后加入剪切搅拌机中,加热至80℃,保温剪切搅拌处理20min,得到油相;
称取SOD2份、玉米低聚肽30份、酪蛋白酸钠1份、水686份,混合加入剪切搅拌机中,加热至70℃,搅拌均匀,得到水相;
将油相缓慢加入至水相中,加入的过程中进行剪切搅拌,完全加入后剪切搅拌20min,得到初乳;
设置高压均质机的参数为:一级压力600bar,二级压力为80bar,对初乳进行高压均质处理6次,均质完成后灌装处理,每个单元灌装30ml;
灌装完成后,在105-121℃下,灭菌处理30min,得到解酒组合物。
实施例5
称取松子油20份、磷脂酰胆碱20份、美藤果油100份、山梨醇肝脂肪酸酯10份,混合后加入剪切搅拌机中,加热至90℃,保温剪切搅拌处理20min,得到油相;
称取SOD5份、玉米低聚肽50份、山梨醇肝脂肪酸酯10份、水785份,混合加入剪切搅拌机中,加热至80℃,搅拌均匀,得到水相;
将油相缓慢加入至水相中,加入的过程中进行剪切搅拌,完全加入后剪切搅拌30min,得到初乳;
设置高压均质机的参数为:一级压力800bar,二级压力为100bar,对初乳进行高压均质处理10次,均质完成后灌装处理,每个单元灌装30ml;
灌装完成后,在105-121℃下,灭菌处理30min,得到解酒组合物。
对比例1
称取大豆磷脂20份、椰子油30份、甘油脂肪酸酯1份,混合后加入剪切搅拌机中,加热至60℃,保温剪切搅拌处理20min,得到油相;
称取SOD5份、玉米低聚肽5份、蔗糖脂肪酸酯10份、水929份,混合加入剪切搅拌机中,加热至60℃,搅拌均匀,得到水相;
将油相缓慢加入至水相中,加入的过程中进行剪切搅拌,完全加入后剪切搅拌20min,得到初乳;
设置高压均质机的参数为:一级压力200bar,二级压力为30bar,对初乳进行高压均质处理3次,均质完成后灌装处理,每个单元灌装30ml;
灌装完成后,在105-121℃下,灭菌处理20min,得到解酒组合物。
对比例2
称取松子油20份、大豆磷脂20份、椰子油30份、蔗糖脂肪酸酯1份,混合后加入剪切搅拌机中,加热至60℃,保温剪切搅拌处理20min,得到油相;
称取玉米低聚肽5份、甘油脂肪酸酯10份、水914份,混合加入剪切搅拌机中,加热至60℃,搅拌均匀,得到水相;
将油相缓慢加入至水相中,加入的过程中进行剪切搅拌,完全加入后剪切搅拌20min,得到初乳;
设置高压均质机的参数为:一级压力200bar,二级压力为30bar,对初乳进行高压均质处理3次,均质完成后灌装处理,每个单元灌装30ml;
灌装完成后,在105-121℃下,灭菌处理20min,得到解酒组合物。
对比例3
称取松子油20份、大豆磷脂20份、椰子油30份、蔗糖脂肪酸酯1份,混合后加入剪切搅拌机中,加热至60℃,保温剪切搅拌处理20min,得到油相;
称取SOD5份、甘油脂肪酸酯10份、水914份,混合加入剪切搅拌机中,加热至60℃,搅拌均匀,得到水相;
将油相缓慢加入至水相中,加入的过程中进行剪切搅拌,完全加入后剪切搅拌20min,得到初乳;
设置高压均质机的参数为:一级压力200bar,二级压力为30bar,对初乳进行高压均质处理3次,均质完成后灌装处理,每个单元灌装30ml;
灌装完成后,在105-121℃下,灭菌处理20min,得到解酒组合物。
验证试验
1.验证对象
选取96例健康受试者,男女各48例,均分为8组,每组12例,男女各6例,96例健康受试者均有饮酒史,8组验证对象在年龄、性别、健康等基本资料方面差异均无统计学意义(P>0.05),可展开对比。
2.试验器材及材料
乙醇标准溶液,乙醛标准溶液,叔丁醇标准溶液(内标),酒精含量吹气检测仪,醋酸洗必泰消毒液,自动顶空-气象色谱-质谱,白酒,上述实施例1-5以及对比例1-3制备得到的解酒组合物。
3.试验方法
本试验分为四个周期,一天一夜为一个周期,于每个周期的下午四点,在饮酒前0min以及饮酒后的15min,30min,45min,60min,75min,90min,120min后进行酒精呼气检测,记录呼气酒精含量,呼气检测时需吐出完整一口气,设备排空后,开始读数。饮酒后需要饮用50ml水,并进行漱口,使口腔无其他残留固体或液体,保证呼气的准确,同时,在饮酒前的0min以及饮酒后的5min,15min,30min,45min,60min,75min,90min,120min的时间点抽取静脉血4ml,抽血时用醋酸洗必泰消毒液(不含乙醇)对抽血部位进行消毒,血液样本抽取后,密封于-70℃保存,供自动顶空-气象色谱-质谱检测。
具体检测周期如下表所示,一个周期内饮酒量60ml,供饮白酒为同度数的二锅头,解酒组合物的饮用量为60ml:
4.评价方法
对同一组内同一周期相同时间点不同个体的呼气酒精含量数据取算数平均值,对同一组内同一周期相同时间点不同个体的乙醇、乙醛和叔丁醇的含量取算数平均值,得到如下结果:
实施例1呼气酒精含量(mg/100ml):
实施例1 | 0min | 15min | 30min | 45min | 60min | 75min | 90min | 120min |
第一周期 | 0 | 41.7 | 122.2 | 110 | 100.8 | 69.1 | 25.7 | 0 |
第二周期 | 0 | 64.2 | 45.8 | 35.6 | 44.2 | 21.8 | 0 | 0 |
第三周期 | 0 | 32.7 | 0 | 0 | 0 | 0 | 0 | 0 |
第四周期 | 0 | 90.2 | 80 | 70 | 66 | 44 | 11 | 0 |
实施例1血液中乙醇和乙醛含量(mg/100ml)
实施例2呼气酒精含量(mg/100ml):
实施例1 | 0min | 15min | 30min | 45min | 60min | 75min | 90min | 120min |
第一周期 | 0 | 42.2 | 122.5 | 111.1 | 101.4 | 68.8 | 26.4 | 0 |
第二周期 | 0 | 61.4 | 72.5 | 49.6 | 42.4 | 26.3 | 18.4 | 0 |
第三周期 | 0 | 45.3 | 6.6 | 0 | 0 | 0 | 0 | 0 |
第四周期 | 0 | 76.5 | 65.2 | 57.1 | 48.2 | 22.5 | 0 | 0 |
实施例2血液中乙醇、乙醛含量(mg/100ml)
实施例3呼气酒精含量(mg/100ml):
实施例1 | 0min | 15min | 30min | 45min | 60min | 75min | 90min | 120min |
第一周期 | 0 | 40.9 | 122.6 | 107.8 | 98.9 | 67.4 | 21 | 0 |
第二周期 | 0 | 48.7 | 46.2 | 34.3 | 32.2 | 16.6 | 0 | 0 |
第三周期 | 0 | 28.4 | 1.3 | 0 | 0 | 0 | 0 | 0 |
第四周期 | 0 | 45.7 | 40.8 | 36.2 | 34.4 | 24.5 | 6.6 | 0 |
实施例3血液中乙醇、乙醛含量(mg/100ml)
实施例4呼气酒精含量(mg/100ml):
实施例1 | 0min | 15min | 30min | 45min | 60min | 75min | 90min | 120min |
第一周期 | 0 | 42.8 | 123.1 | 112.5 | 104.8 | 72.4 | 31.1 | 0 |
第二周期 | 0 | 65.7 | 58.6 | 44.3 | 39.7 | 22.4 | 0 | 0 |
第三周期 | 0 | 42.9 | 21 | 5.1 | 0 | 0 | 0 | 0 |
第四周期 | 0 | 86.9 | 78.4 | 71.5 | 65 | 44.8 | 11.8 | 0 |
实施例4血液中乙醇、乙醛含量(mg/100ml)
实施例5呼气酒精含量(mg/100ml):
实施例1 | 0min | 15min | 30min | 45min | 60min | 75min | 90min | 120min |
第一周期 | 0 | 41.5 | 121.1 | 108.2 | 100 | 68.8 | 24.2 | 0 |
第二周期 | 0 | 65 | 46.7 | 34.2 | 38.2 | 21.2 | 0 | 0 |
第三周期 | 0 | 33.5 | 8.2 | 0 | 0 | 0 | 0 | 0 |
第四周期 | 0 | 91.4 | 82.7 | 71.8 | 61.6 | 42.2 | 10.8 | 0 |
实施例5血液中乙醇、乙醛含量(mg/100ml)
对比例1呼气酒精含量(mg/100ml):
实施例1 | 0min | 15min | 30min | 45min | 60min | 75min | 90min | 120min |
第一周期 | 0 | 41.6 | 120.1 | 110.7 | 101.5 | 69.1 | 25.5 | 0 |
第二周期 | 0 | 58.2 | 119.4 | 108.6 | 99.3 | 65.2 | 24.9 | 0 |
第三周期 | 0 | 40.2 | 112.6 | 104.8 | 99.4 | 64.3 | 23.5 | 0 |
第四周期 | 0 | 55.2 | 118.5 | 105.6 | 100.6 | 65.8 | 23.6 | 0 |
对比例1血液中乙醇、乙醛含量(mg/100ml)
对比例2呼气酒精含量(mg/100ml):
实施例1 | 0min | 15min | 30min | 45min | 60min | 75min | 90min | 120min |
第一周期 | 0 | 42.6 | 120.2 | 108.9 | 102.2 | 72.1 | 29 | 0 |
第二周期 | 0 | 63.2 | 44.2 | 34.8 | 45.7 | 25.8 | 1.2 | 0 |
第三周期 | 0 | 44.6 | 55.6 | 48.2 | 40.4 | 21 | 0 | 0 |
第四周期 | 0 | 88.4 | 78.5 | 71.4 | 67.2 | 45 | 12.2 | 0 |
对比例2血液中乙醇、乙醛含量(mg/100ml)
对比例3呼气酒精含量(mg/100ml):
实施例1 | 0min | 15min | 30min | 45min | 60min | 75min | 90min | 120min |
第一周期 | 0 | 42.7 | 118.2 | 109.8 | 102.2 | 72.5 | 27.6 | 0 |
第二周期 | 0 | 61.2 | 43.4 | 34.2 | 42.8 | 25.5 | 0 | 0 |
第三周期 | 0 | 45.1 | 66.7 | 50.8 | 40.6 | 16.8 | 0 | 0 |
第四周期 | 0 | 89.6 | 77.8 | 69.6 | 64.7 | 46.8 | 15.3 | 0 |
对比例3血液中乙醇、乙醛含量(mg/100ml)
上述试验数据可以看出,在饮酒后使用本发明制备得到的解酒组合物,可以快速降解体内的乙醇,而在饮酒前使用或者饮酒前后均使用一半量时,也能够起到加快降解体内乙醇的作用,相对饮酒后使用效果稍差,但是饮酒前和/或饮酒后进行本发明饮品的饮用,均可以在一定程度上起到抑制酒精快速被肠道吸收,同时加速体内对酒精以及乙醛的代谢能力,而对比实施例与对比例的数据可以看出:
对比例1减少了松子油,受试者在使用对比例1后,虽然同样可以快速加快肠道吸收,但是体内酒精和乙醛的代谢速度明显大幅度下降,甚至与第一周期数据接近,显然松子油的加入对于解酒作用具有较大程度的帮助作用。
对比例2减少了SOD,虽然同样产生的一定解酒能力,但是相比实施例数据而言,明显存在解酒能力的下降,证明加入了松子油,在没有SOD辅助的作用下,本发明的产品同样无法达到更好的解酒效果。
对比例3减少了玉米低聚肽,同样可以产生一定解酒能力,但是解酒能力显然没有实施例所带来的效果好,因此玉米低聚肽的加入对解酒能力的提高同样有重要的辅助作用。
安全性评价:
以上五组实施例在试验过程中,受试人员均未见明显不良反应,具有较好的安全性。
以上所述仅为本发明的较佳实施方式而已,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
1.一种解酒组合物,其特征在于,包括如下组分:松子油、磷脂、食用油、SOD、玉米低聚肽、乳化剂和水。
2.如权利要求1所述的解酒组合物,其特征在于:解酒组合物按质量百分比为100%计算,包括:松子油0.2-5.0%,磷脂0.2-3.0%,食用油0.1-30%,SOD0.01-0.5%,玉米低聚肽0.1-5%,乳化剂0.2-2.0%,余量为水。
3.如权利要求1所述的解酒组合物,其特征在于:所述松子油包括华山松子油、白皮松子油、长白松子油和红松子油中的至少一种。
4.如权利要求1所述的解酒组合物,其特征在于,磷脂包括大豆磷脂、改性大豆磷脂、蛋黄卵磷脂和磷脂酰胆碱中的至少一种。
5.如权利要求1所述的解酒组合物,其特征在于,食用油包括大豆油、中链甘油三酸酯、水飞蓟籽油、椰子油、美藤果油、火麻油和鱼油中的至少一种。
6.如权利要求1所述的解酒组合物,其特征在于,乳化剂包括甘油脂肪酸酯、蔗糖脂肪酸酯、酪蛋白酸钠、蔗糖酯、山梨醇酐脂肪酸酯、丙二醇脂肪酸酯、硬脂酰乳酸盐和双乙酰酒石酸单甘油酯中的至少一种。
7.如权利要求1所述的解酒组合物,其特征在于,还包括助剂,助剂包括pH调节剂、稳定剂和甜味剂中的至少一种。
8.权利要求1-7中任一所述的解酒组合物的制备方法,其特征在于,包括如下步骤:
按投料量称取SOD、玉米低聚肽和部分乳化剂,加入水中加热至30-90℃,混合均匀得到水相;
按投料量称取松子油、磷脂、食用油和剩余乳化剂,加热至40-80℃,混合均匀得到油相;
混合油相和水相得到解酒组合物。
9.如权利要求8所述的解酒组合物的制备方法,其特征在于,混合油相和水相的方法包括:将油相加入水相,加入的过程中进行剪切,剪切完毕用高压均质机进行均质处理,得到解酒组合物。
10.一种如权利要求1-7中任一所述的解酒组合物在食品或药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310560356.XA CN116508991B (zh) | 2023-05-17 | 2023-05-17 | 解酒组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310560356.XA CN116508991B (zh) | 2023-05-17 | 2023-05-17 | 解酒组合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116508991A true CN116508991A (zh) | 2023-08-01 |
CN116508991B CN116508991B (zh) | 2023-11-24 |
Family
ID=87408155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310560356.XA Active CN116508991B (zh) | 2023-05-17 | 2023-05-17 | 解酒组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116508991B (zh) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103211856A (zh) * | 2013-05-03 | 2013-07-24 | 李成仁 | 一种可以解酒的油类混合物 |
TW201440807A (zh) * | 2013-03-22 | 2014-11-01 | Kobayashi Pharma | 經口組成物 |
CN108208853A (zh) * | 2018-01-04 | 2018-06-29 | 山东凤凰生物有限公司 | 一种解酒护肝益生菌低聚肽复合制剂及制备方法 |
CN108404108A (zh) * | 2018-04-13 | 2018-08-17 | 覃静欣 | 一种复合玉米低聚肽胶囊及其制备方法 |
CN109432411A (zh) * | 2018-12-17 | 2019-03-08 | 湖南泽迈生物科技有限公司 | 一种具有护胃、保肝、解酒作用的药膳配方及其制备方法 |
CN109699797A (zh) * | 2019-02-22 | 2019-05-03 | 广州市人健生物科技有限公司 | 一种具有解酒效果的玉米低聚肽压片糖果及其制备工艺 |
CN113491720A (zh) * | 2020-03-18 | 2021-10-12 | 绿茵生技股份有限公司 | 牛樟芝用于解酒及/或增加酒精代谢的用途 |
CN114246941A (zh) * | 2021-10-18 | 2022-03-29 | 广东昊邦医药健康有限责任公司 | 一种具有预防宿醉和解酒保肝的组合物及其应用 |
CN114271490A (zh) * | 2021-12-02 | 2022-04-05 | 深圳中科欣扬生物科技有限公司 | 一种含sod和麦角硫因的抗疲劳抗氧化和解酒功能的保健配方 |
CN114470176A (zh) * | 2021-12-08 | 2022-05-13 | 深圳中科欣扬生物科技有限公司 | 一种防止宿醉、缓解饮酒后不适的饮用水 |
-
2023
- 2023-05-17 CN CN202310560356.XA patent/CN116508991B/zh active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201440807A (zh) * | 2013-03-22 | 2014-11-01 | Kobayashi Pharma | 經口組成物 |
CN103211856A (zh) * | 2013-05-03 | 2013-07-24 | 李成仁 | 一种可以解酒的油类混合物 |
CN108208853A (zh) * | 2018-01-04 | 2018-06-29 | 山东凤凰生物有限公司 | 一种解酒护肝益生菌低聚肽复合制剂及制备方法 |
CN108404108A (zh) * | 2018-04-13 | 2018-08-17 | 覃静欣 | 一种复合玉米低聚肽胶囊及其制备方法 |
CN109432411A (zh) * | 2018-12-17 | 2019-03-08 | 湖南泽迈生物科技有限公司 | 一种具有护胃、保肝、解酒作用的药膳配方及其制备方法 |
CN109699797A (zh) * | 2019-02-22 | 2019-05-03 | 广州市人健生物科技有限公司 | 一种具有解酒效果的玉米低聚肽压片糖果及其制备工艺 |
CN113491720A (zh) * | 2020-03-18 | 2021-10-12 | 绿茵生技股份有限公司 | 牛樟芝用于解酒及/或增加酒精代谢的用途 |
CN114246941A (zh) * | 2021-10-18 | 2022-03-29 | 广东昊邦医药健康有限责任公司 | 一种具有预防宿醉和解酒保肝的组合物及其应用 |
CN114271490A (zh) * | 2021-12-02 | 2022-04-05 | 深圳中科欣扬生物科技有限公司 | 一种含sod和麦角硫因的抗疲劳抗氧化和解酒功能的保健配方 |
CN114470176A (zh) * | 2021-12-08 | 2022-05-13 | 深圳中科欣扬生物科技有限公司 | 一种防止宿醉、缓解饮酒后不适的饮用水 |
Non-Patent Citations (1)
Title |
---|
作者不详: "喝了白酒要怎么退,如何快速退酒", 美酒网HTTPS://WWW.MEIJIU.COM/CS/1458247.HTML * |
Also Published As
Publication number | Publication date |
---|---|
CN116508991B (zh) | 2023-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107149068A (zh) | 一种蜂蜜醒酒饮料及其制备方法 | |
CN101664136A (zh) | 一种高活性营养纳豆的制备方法及其应用 | |
KR20140103572A (ko) | 아르기닌, 마카추출분말, 구연산 및 폴리덱스트로스를 주성분으로 함유하는 기능성 액상 조성물 | |
EP2532351A1 (en) | Agent for improving motility function | |
KR101447231B1 (ko) | 숙취해소환의 제조 방법 및 상기 방법에 의하여 제조된 숙취해소환 | |
CN103251698B (zh) | 一种具有解酒保肝护胃功效的葛根饮液及其制法 | |
CN110122707A (zh) | 一种解酒果汁饮料及其制备方法 | |
US20230364169A1 (en) | Use of antrodia cinnamomea for increasing alcohol metabolism or/and hangover | |
CN109527190A (zh) | 黑木耳复合小分子肽粉的制备方法及其应用 | |
CN116508991B (zh) | 解酒组合物及其制备方法和应用 | |
KR101552970B1 (ko) | 삼채 추출물을 유효성분으로 포함하는 간 기능 개선 또는 간 손상 보호용 조성물 | |
CN112472719A (zh) | 一种以蒙花苷为主要成分防治围产期奶牛脂肪肝的粉剂 | |
KR20210157987A (ko) | 숙취 해소 및 간 기능 개선용 식품 조성물 | |
KR100780120B1 (ko) | 공액 리놀레산을 함유하는 숙취해소 및 알코올성 질병예방을 위한 기능성 식품 | |
CN110522028A (zh) | 一种护肝抗疲劳的组合物及其应用 | |
CN109275914A (zh) | 黑木耳多肽功能食用组合物及其制备方法和应用 | |
KR102367717B1 (ko) | 숙취해소 및 간기능 개선용 식품 조성물 및 이를 이용한 건강 기능식품 | |
CN113143988B (zh) | 油甘萃取物用于解酒、预防酒精或其代谢产物相关疾病的用途 | |
CN108720013A (zh) | 一组由果糖和茶叶提取物组成的醒酒护肝的保健食品的配方及生产工艺 | |
EP4209135A1 (en) | Composition for removing hangover and improving liver function | |
CN115299614B (zh) | 一种解酒组合物、解酒果冻及其制备方法与应用 | |
TWI708610B (zh) | 油甘萃取物用於解酒、預防酒精或其代謝產物相關疾病之用途 | |
KR102668450B1 (ko) | 청각 추출물 또는 이의 분획물을 유효성분으로 포함하는 숙취해소제 | |
CN114712424B (zh) | 一种具有解酒保肝作用的中药制剂及其制备方法和应用 | |
CN116439336A (zh) | 一种沙棘植物饮料配方及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |